MYMX : Summary for MYMETICS CORP COM USD0.01 - Yahoo Finance

U.S. Markets close in 2 hrs 3 mins

Mymetics Corporation (MYMX)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.01-0.00 (-1.36%)
As of 12:47 PM EST. Market open.
People also watch:
LCARPPMDOXISKDUSHMGN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.01
Open0.01
Bid0.00 x
Ask0.00 x
Day's Range0.01 - 0.02
52 Week Range0.01 - 0.08
Volume383,500
Avg. Volume153,407
Market Cap4.4M
Beta-5.87
PE Ratio (TTM)-1.32
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire7 days ago

    Mymetics Starts Research Project with Sanofi for Influenza Vaccines

    EPALINGES, Switzerland, Dec. 1, 2016 /PRNewswire/ -- Mymetics Corporation (MYMX), a pioneer and leader in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that its subsidiary Mymetics B.V. has agreed on a research project with Sanofi Pasteur, the vaccine division of Sanofi (SNY). The project will investigate the immunogenicity of influenza vaccines based on Mymetics' proprietary virosome technology platform in pre-clinical settings. "We are very excited to start this initial collaboration project with Sanofi, a world leader in the vaccine industry," said Ronald Kempers, CEO of Mymetics.

  • Mymetics Corp. :MYMX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 17, 2016
    Capital Cube21 days ago

    Mymetics Corp. :MYMX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 17, 2016

    Categories: Yahoo Finance Get free summary analysis Mymetics Corp. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of Mymetics Corp. – Vical Incorporated, Novartis AG Sponsored ADR and ADMA Biologics, Inc. (VICL-US, NVS-US and ADMA-US) that have also reported for this period. Highlights Summary numbers: Revenues of ... Read more (Read more...)

  • PR Newswire3 months ago

    Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development

    EPALINGES, Switzerland, Sept. 19, 2016 /PRNewswire/ -- Mymetics Corporation (MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious agents across mucosal membranes, announced today the continuation of the collaboration with the Texas Biomedical Research Institute related to the Mymetics' HIV vaccine candidate. In April this year, both organizations announced the results from a non-human primate study which was led by Dr. Ruth Ruprecht, Scientist & Director of the Texas Biomed AIDS Research Program and funded by the Bill & Melinda Gates Foundation, where Mymetics' two-component virosome-based HIV vaccine was able to show significant efficacy of 87% in delaying the time to persistent infection versus the control group after seven intravaginal virus challenges.